Tasigna Neoadjuvant Gastrointestinal Stromal Tumor (GIST)

Summary

The goal of this clinical research study is to learn if Tasigna® (nilotinib) can cause tumor cells to shrink and/or die in patients with GIST who are scheduled for surgery or may be eligible for surgery. The safety of this drug will be studied. Researchers also want to use imaging scans to study the changes in tumor size that may be caused by using nilotinib.

Timeline

Start

2011-01

Primary completion

—

Completion

—

Drugs

Indications